Development
Partner Therapeutics' zenocutuzumab shows continued benefit beyond progression in NRG1 fusion lung cancer
Partner Therapeutics (PTx), a Massachusetts-based biotechnology company, announced new findings from a post hoc analysis of the eNRGy trial evaluating...
PMV Pharmaceuticals Publishes First-in-Human Rezatapopt p53 Reactivator Data in Advanced Solid Tumors
PMV Pharmaceuticals, a Princeton-based precision oncology company listed on Nasdaq as PMVP, has published Phase 1 results from its PYNNACLE study of...
Bristol Myers Squibb's mezigdomide shows positive phase 3 results in relapsed multiple myeloma
Bristol Myers Squibb announced positive interim results from the SUCCESSOR-2 study, a Phase 3 trial evaluating oral mezigdomide in combination with...
Incannex advances IHL-42X development strategy following positive Phase 2 obstructive sleep apnea results
Incannex Healthcare, a Melbourne and New York-based clinical-stage biopharmaceutical company, announced an updated clinical development strategy for IHL-42X...
MoonLake's sonelokimab sustains deep responses in Phase III hidradenitis suppurativa trials at week 40
MoonLake Immunotherapeutics (Nasdaq: MLTX) reported Week 40 data from its Phase III VELA program evaluating sonelokimab in hidradenitis suppurativa, showing...
Akeso advances AK146D1 and AK138D1 into phase II trials for advanced solid tumors
Akeso, Inc. (Hong Kong; HKEX: 9926.HK) announced on March 24, 2026, that it has received clearance from China's National Medical Products Administration to...
Abbisko Therapeutics Launches Phase I/II Trial of ABSK141 KRAS G12D Inhibitor in Solid Tumors
For decades, the KRAS G12D mutation sat at the top of oncology's most-wanted list — prevalent, lethal, and stubbornly resistant to pharmacological...
Tetragon Biosciences Launches Phase 1 Trial of TET2 Agonist GLIX1 in Recurrent Glioblastoma
Tetragon Biosciences has opened a Phase 1 clinical trial of GLIX1, an oral small molecule that agonizes TET2, in adults with recurrent or progressive...
Aardvark Therapeutics pauses ARD-101 Prader-Willi syndrome trials after cardiac safety signal emerges
Aardvark Therapeutics has voluntarily paused enrollment and dosing in its Phase III HERO trial and open-label extension study evaluating ARD-101 for the...
Idorsia's daridorexant shows positive Phase II results in pediatric insomnia disorder study
Idorsia Ltd, based in Allschwil, Switzerland, reported positive top-line results from a Phase II dose-finding study of daridorexant in pediatric patients...
Eli Lilly's lebrikizumab delivers positive Phase 3 results in pediatric atopic dermatitis trial
Eli Lilly announced positive Phase 3 results for EBGLYSS (lebrikizumab-lbkz) in pediatric patients aged six months to 18 years with moderate-to-severe...
Ascletis reports positive phase II data for ASC30 depot formulation in obesity treatment
Hong Kong-based Ascletis Pharma Inc. announced topline results from a US Phase II study of ASC30, a small molecule GLP-1 receptor agonist formulated as a...
Wave Life Sciences' WVE-007 shows visceral fat reduction in Phase I obesity trial
Wave Life Sciences reported interim WVE-007 clinical data from the Phase I portion of its INLIGHT trial, showing that a single 240 mg dose of the...
Lundbeck's bocunebart meets primary endpoint in Phase IIb migraine prevention trial
Denmark-based H. Lundbeck A/S announced positive topline results from the intravenous dosing arm of its Phase IIb PROCEED trial evaluating bocunebart (Lu...
Structure Therapeutics' aleniglipron achieves 16.3% weight loss in phase 2 obesity trial
Structure Therapeutics (NASDAQ: GPCR), a San Francisco-based clinical-stage biopharmaceutical company, reported topline data from its Phase 2 ACCESS II...
The AllSci Brief
Systematic R&D and deal news. Daily.